23andMe, the Mountain View, CA-based maker of genetic tests for consumers, said today it has raised more than $22 million in a Series C venture financing. The money came from a new investor, Johnson & Johnson Development Corporation, in addition to existing investors New Enterprise Associates and Google Ventures. The financing comes a couple months after 23andMe and other direct-to-consumer genetic test companies were criticized by the U.S. Government Accountability Office, which raised doubts about the usefulness and accuracy of the tests that were publicized at a Congressional hearing. 23andMe’s chief executive, Anne Wojcicki, said in a statement that the new financing “will help us achieve our goal of dramatically accelerating the pace of research and could ultimately make health care research and health care delivery more efficient.”
